|
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Age and the T allele of ARMS2 A69S are the risk factors requiring retreatments, leading to poor visual change in eyes with exudative AMD following the initial 3-monthly IVR.
|
29045945 |
2018 |
|
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Among different genotype combinations ARMS2-CFH and CFH-C3 combinations have the most significant levels of synergism and C3-CFI combination has the most significant level of antagonism in AMD patients.
|
29087762 |
2018 |
|
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Regression analysis showed that ARMS2 TT genotype has a statistically significant effect on RAP versus AMD compared to CFH genotypes (P < 0.001).
|
28005184 |
2017 |
|
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, we confirm that ARMS2, HTRA1 and CFH variants are associated with neovascular AMD in the Thai population.
|
28703135 |
2017 |
|
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
AMD (n=316) was strongly associated with CFH (p=1.78×10(-7)) and ARMS2 genotypes (p=1.67×10(-8)).
|
26614632 |
2016 |
|
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Their genetic susceptibility to AMD was significantly lower than that of neovascular AMD; ARMS2 rs10490924 (p = 0.029), CFH rs800292 (p = 0.013) and genetic risk score calculated from 11 AMD susceptibility genes (p = 3.8 × 10(-3)).
|
26542071 |
2015 |
|
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The risk alleles C in CFH rs1061170 (p < 0.0001, Pearson chi-square) and T in ARMS2 rs10490924 (p < 0.0001), as well as smoking (p < 0.0001), were more prevalent in AMD patients compared with controls.
|
26154559 |
2015 |
|
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association between variants A69S in ARMS2 gene and response to treatment of exudative AMD: a meta-analysis.
|
25185256 |
2015 |
|
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
After adjusting for age, gender, ARMS2 A69S, and CFHI62V, the A allele of rs429608 was significantly protective against neovascular AMD (odds ratio [OR] 0.24, 95% confidence interval [CI] 0.122-0.484, p < 0.001), PCV (OR 0.43, 95% CI 0.262-0.704, p = 0.001), RAP (OR 0.09, 95% CI 0.014-0.581, p = 0.011).
|
24865191 |
2014 |
|
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CFH (rs1410996), HTRA1 (rs112000638) and ARMS2 (rs10490923) gene polymorphisms are associated with AMD risk in Spanish patients.
|
23534868 |
2014 |
|
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
After multivariate adjustment, CFH Y402H and ARMS2 A69S polymorphisms were associated with very high risk for exudative AMD (OR = 6.21 and OR = 11.7, respectively, p < 0.0001).
|
24362810 |
2014 |
|
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
AMD patients with risk variants at rs1061170 (rs1061170" genes_norm="3075">CFH:p.Y402H) and ARMS2 and smokers (≥20 packs/year) were significantly earlier affected by AMD than those carrying the non-risk variants at each locus.
|
23103884 |
2013 |
|
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
AMD-associated variants at the chromosome 10q26 locus and the stability of ARMS2 transcripts.
|
23942973 |
2013 |
|
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A risk allele of ARMS2 A69S was more frequently seen in patients with bilateral AMD (P = .0270) than in those with unilateral AMD.
|
22809783 |
2012 |
|
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CFH, ARMS2 and HTRA1 genotypes may influence patient response to treatment with intravitreal bevacizumab for neovascular AMD.
|
22594510 |
2012 |
|
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
After adjusting for rs11200638, ARMS2 rs10490924 remained significantly associated with exudative AMD (P = 0.011), but not with PCV (P = 0.077).
|
22491416 |
2012 |
|
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
After ranibizumab treatment, AMD patients without risk alleles in the CFH and ARMS2 genes (4.8%) demonstrated a mean VA improvement of 10 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, whereas no VA improvement was observed in AMD patients with 4 CFH and ARMS2 risk alleles (6.9%; P = 0.014).
|
22840423 |
2012 |
|
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Retinal function and CFH-ARMS2 polymorphisms analysis: a pilot study in Italian AMD patients.
|
22552255 |
2012 |
|
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Risk- and non-risk-associated variants at the 10q26 AMD locus influence ARMS2 mRNA expression but exclude pathogenic effects due to protein deficiency.
|
21252205 |
2011 |
|
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Results were then integrated into a meta-analysis of previous studies representing an assessment of the association between the ARMS2 A69S variant and neovascular AMD and/or PCV, comprising a total of 3,828 subjects of Asian descent.
|
22219653 |
2011 |
|
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We identified a sample of patients with neovascular AMD, that in previous studies had been shown to be at elevated risk for the disease through environmental factors such as cigarette smoking and genetic variants including the complement factor H gene (CFH) on chromosome 1q25 and variants in the ARMS2/HtrA serine peptidase 1 (HTRA1) gene(s) on chromosome 10q26.
|
21682878 |
2011 |
|
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Analysis of six genetic risk factors highly associated with AMD in the region surrounding ARMS2 and HTRA1 on chromosome 10, region q26.
|
19933195 |
2010 |
|
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
AMD donors carrying the ARMS2 and HTRA1 risk alleles were the most likely to exhibit elevated CEP markers.
|
20238042 |
2010 |
|
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
AMD donors carrying the ARMS2 and HTRA1 risk alleles were the most likely to exhibit elevated CEP markers.
|
19202148 |
2009 |
|
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
AMD is a complex disorder caused by genetic and environmental factors in which single nucleotide polymorphisms (SNPs) in the genes CFH and LOC387715/HTRA1/ARMS2 have prognostic importance for progression to advanced AMD (with visual loss).
|
19015224 |
2009 |